SUMMIT THERAPEUTICS PLC

NASDAQ: SMMT (Summit Therapeutics Inc.)

Kemas kini terakhir: 25 Nov, 3:28PM

17.64

-0.20 (-1.12%)

  • 1H -1.12%
  • 5H -1.40%
  • 1B -2.97%
  • 6B -18.18%
  • Tahun Ke Tarikh -3.87%
  • 1T -5.47%
  • 5T 253.51%
Penutupan Terdahulu 17.84
Buka 17.83
Jumlah Dagangan 1,724,982
Purata Dagangan (3B) 4,015,173
Modal Pasaran 13,131,966,464
Harga / Buku (P/B) 70.90
Julat 52 Minggu
15.55 (-11%) — 36.91 (109%)
Tarikh Pendapatan 20 Oct 2025
EPS Cair (TTM) -0.340
Jumlah Hutang/Ekuiti (D/E MRQ) 1.87%
Nisbah Semasa (MRQ) 10.63
Aliran Tunai Operasi (OCF TTM) -173.14 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -104.80 M
Pulangan Atas Aset (ROA TTM) -52.50%
Pulangan Atas Ekuiti (ROE TTM) -123.93%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Summit Therapeutics Inc. Menaik Menaik

AISkor Stockmoo

3.1
Konsensus Penganalisis 3.5
Aktiviti Orang Dalam NA
Volatiliti Harga 4.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata 3.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SMMT 13 B - - 70.90
ALNY 62 B - 1,682.64 267.34
INCY 20 B - 17.41 4.29
ABVX 9 B - - 8.74
ONC 37 B - 649.80 8.85
BMRN 10 B - 19.85 1.72

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Mid Core
% Dimiliki oleh Orang Dalam 84.32%
% Dimiliki oleh Institusi 13.52%

Pemilikan

Nama Tarikh Syer Dipegang
Apeiron Capital Ltd 30 Sep 2025 1,310,941
Julat 52 Minggu
15.55 (-11%) — 36.91 (109%)
Julat Harga Sasaran
16.00 (-9%) — 40.00 (126%)
Tinggi 40.00 (HC Wainwright & Co., 126.76%) Beli
40.00 (Guggenheim, 126.76%) Beli
40.00 (JMP Securities, 126.76%) Beli
40.00 (Citigroup, 126.76%) Beli
Median 40.00 (126.76%)
Rendah 16.00 (Barclays, -9.30%) Jual
Purata 35.20 (99.55%)
Jumlah 4 Beli, 1 Jual
Harga Purata @ Panggilan 19.34
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Guggenheim 22 Oct 2025 40.00 (126.76%) Beli 19.16
Barclays 21 Oct 2025 16.00 (-9.30%) Jual 18.74
17 Sep 2025 13.00 (-26.30%) Jual 18.09
HC Wainwright & Co. 21 Oct 2025 40.00 (126.76%) Beli 18.74
16 Sep 2025 50.00 (183.45%) Beli 18.12
Citigroup 20 Oct 2025 40.00 (126.76%) Beli 20.04
JMP Securities 20 Oct 2025 40.00 (126.76%) Beli 20.04

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
05 Dec 2025 Pengumuman Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Nov 2025 Pengumuman Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China
04 Nov 2025 Pengumuman Summit Therapeutics to Present at Upcoming Investor Conferences
31 Oct 2025 Pengumuman Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
22 Oct 2025 Pengumuman Summit Therapeutics Raises $500 Million in Private Placement
20 Oct 2025 Pengumuman Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025
19 Oct 2025 Pengumuman Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
17 Oct 2025 Pengumuman Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer
15 Oct 2025 Pengumuman Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025
24 Sep 2025 Pengumuman HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025
24 Sep 2025 Pengumuman Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Sep 2025 Pengumuman Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332
07 Sep 2025 Pengumuman Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda